Damage Control Surgery Over the World in Acute Diverticulitis (DACOSAD) (DACOSAD)

June 4, 2024 updated by: Link Campus University

An International Study Investigating the Adoption and Outcome of Damage Control Surgery in Hinchey III-IV Acute Diverticulitis (DACOSAD)

To analyze the possible benefit of damage control surgery by performing bowel resection, open abdomen, and delayed anastomosis in the treatment of Hinchey III or IV diverticulitis.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

Hartmann procedure (HP) is still widely performed in the treatment of purulent or fecal generalized peritonitis as a consequence of a complicated acute large bowel diverticulitis (the so labeled III and IV grade of the Hinchey's classification). More than half of those patients do not undergo to stoma reversal because of its association with significant morbidity and mortality. To date, the use of resection with primary anastomosis (PA) should be preferred, as it is reported in the literature that it is more favorable than HP in terms of morbidity, mortality, and length of postoperative stay. However, PA is often reserved for younger patients with few co-morbidities and a lesser degree of peritoneal contamination while HP is performed in the elderly. Initially described for the treatment of major abdominal injuries, indications for Damage Control Surgery (DCS) have subsequently been extended to septic shock, abdominal compartment syndrome and impossibility to perform a primary closure. In the last decade, DCS has emerged as a valid alternative to HP and Resection-Anastomosis (RA) in patients presenting a severe sepsis caused by purulent or fecal peritonitis in acute diverticulitis. Although DCS is cited as an option in case of impaired hemodynamic status in face of perforated acute diverticulitis, there is still no consensus about such use of DCS. Previous study demonstrated that DCS reduce the Hartmann rate in patients otherwise scheduled for such procedure.

The aim of this study was to describe the potential rationale and outcome of the Damage Control Surgery in patients with purulent and fecal peritonitis.

Study Type

Observational

Enrollment (Estimated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Santiago de Chile, Chile
        • Enrolling by invitation
        • Hospital de Urgencia Asistencia Publica
      • Caserta, Italy, 81100
        • Recruiting
        • UOC Chirurgia Generale Ospedale Sant'Anna e San Sebastiano
        • Contact:
          • Mauro Andreano, Prof.
        • Principal Investigator:
          • Alberto Mingione, MD
      • Pisa, Italy, 56124
        • Recruiting
        • UOC Chirurgia Generale, Urgenza e Trauma Pisa University Hospital
        • Principal Investigator:
          • Dario Tartaglia, MD
        • Contact:
          • Massimo Chiarugi, MD, FACS
      • Roma, Italy, 00193
        • Recruiting
        • UOC Chirurgia Generale ed Urgenza Ospedale Santo Spirito in Sassia
        • Contact:
          • Luca Lepre, MD, PhD
        • Principal Investigator:
          • Michela Giulii Capponi, MD
      • Roma, Italy
        • Recruiting
        • Dipartimento di Chirurgia AOU Policlinico Umberto I Sapienza Università di Roma
        • Contact:
          • Andrea Mingoli, Prof.
        • Principal Investigator:
          • Gioia Brachini, MD, PhD
        • Sub-Investigator:
          • Bruno Cirillo, MD, PhD
      • Roma, Italy, 00168
        • Recruiting
        • Fondazione Policlinico Universitario "A.Gemelli"
        • Principal Investigator:
          • Pietro Fransvea, MD
        • Contact:
          • Gabriele Sganga, MD, FACS
    • Lazio
      • Roma, Lazio, Italy, 00128
        • Recruiting
        • Fondazione Policlinico Universitario Campus Bio-Medico
        • Contact:
          • Marco Caricato, MD, PhD
        • Principal Investigator:
          • Gabriella T Capolupo, MD, PhD
    • Roma
      • Ostia, Roma, Italy, 00122
        • Recruiting
        • UOC Chirurgia Generale - Ospedale GB Grassi
        • Contact:
          • Gianluca Mazzoni, MD, PhD
        • Contact:
        • Principal Investigator:
          • Loretta Di Cristofaro, MD
      • Palestrina, Roma, Italy, 00036
        • Recruiting
        • UOC Chirurgia Generale Ospedale Coniugi Bernardini
        • Contact:
          • Gianluca Liotta, MD, PhD
          • Phone Number: +39 06 95321

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Same as above

Description

Inclusion Criteria:

  • Patients >18 year-old underwent surgery for Hinchey III and IV and submitted to resection, clip and drop, and open abdomen

Exclusion Criteria:

  • Subjects <18 year-old

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mortality
Time Frame: 60 days
Mortality rate related to treatment
60 days
Morbidity
Time Frame: 60 days
Morbidity rate defined by the presence of at least one grade of the Clavien-Dindo Classification scoring system
60 days
Total morbidity
Time Frame: 60 days
Morbidity calculated by means of the Comprehensive Complication Index
60 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Upfront Hartmann rate
Time Frame: 60 days
Observed to expected (O:E) ratio of Hartmann's procedures
60 days
Length of stay (LOS)
Time Frame: 60 days
Days of stay as inpatient
60 days
ICU length of stay
Time Frame: 60 days
Days of stay in ICU
60 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Gianluca Costa, Prof., Link Campus University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2020

Primary Completion (Estimated)

December 31, 2024

Study Completion (Estimated)

June 1, 2025

Study Registration Dates

First Submitted

May 20, 2024

First Submitted That Met QC Criteria

May 20, 2024

First Posted (Actual)

May 24, 2024

Study Record Updates

Last Update Posted (Actual)

June 5, 2024

Last Update Submitted That Met QC Criteria

June 4, 2024

Last Verified

June 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Open Abdomen

Clinical Trials on Damage Control Surgery

3
Subscribe